tradingkey.logo

Roivant swings to Q3 loss as revenue drops

ReutersFeb 6, 2026 12:12 PM


Overview

  • Biopharmaceutical firm's Q3 revenue drops to $2 mln from $9 mln yr-ago

  • Posts Q4 net loss vs profit in year-ago quarter

  • Roivant reported $4.5 bln in cash and marketable securities as of Dec 31, 2025


Outlook

  • Roivant plans Phase 3 study for brepocitinib in cutaneous sarcoidosis starting in 2026

  • Company expects topline data from brepocitinib NIU trial in second half of 2026

  • Roivant actively exploring additional indications for brepocitinib


Result Drivers

  • R&D EXPENSES - Increase in R&D expenses driven by program-specific costs and share-based compensation

  • STRONG CASH POSITION - Reported $4.5 bln in cash and marketable securities as of Dec 31, 2025


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

$2 mln

Q3 EPS

-$0.38

Q3 Net Income

-$313.70 mln

Q3 Income From Operations

Miss

-$339.15 mln

-$306.38 mln (6 Analysts)

Q3 Operating Expenses

$341.15 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Roivant Sciences Ltd is $26.00, about 23% above its February 5 closing price of $21.14

Press Release: ID:nGNX547nb2

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI